Clinical Study
Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China
Table 2
Virological response during and after treatment.
| | | SOF+DCV
N=96 | SOF+LDV
N=99 | SOF+VEL
N=31 | Total
N=226 |
| | HCV RNA <15 IU/ml, n/N (%) | | | | | | During treatment | | | | | | Week 1 | 65/96 (68%) | 71/99 (72%) | 20/31 (71%) | 159/226 (70%) | | Week 4 | 88/96 (92%) | 93/99 (94%) | 30/31 (97%) | 211/226 (95%) | | Week 8 | 95/96 (99%) | 99/99 (100%) | 31/31 (100%) | 225/226 (99%) | | Week 12 | 96/96 (100%) | 99/99 (100%) | 31/31 (100%) | 226/226 (100%) | | After treatment | | | | | | SVR 4 | 94/96 (98%) | 99/99 (100%) | 31/31 (100%) | 223/226 (99%) | | SVR12 | 89/96 (93%) | 96/99 (97%) | 31/31 (100%) | 216/226 (96%) | | SVR12, n (%) | | | | | | Treatment history | | | | | | Treatment naïve | 52/54 (96%) | 49/50 (98%) | 21/21 (100%) | 122/125 (98%) | | Treatment-experienced | 37/42 (88%) | 47/49 (96%) | 10/10 (100%) | 94/101 (93%) | | HCV genotype | | | | | | 1b | 55/55 (100%) | 70/73 (96%) | 12/12 (100%) | 137/140 (98%) | | 2a | 11/13 (85%) | 0 | 6/6 (100%) | 17/19 (89%) | | 3a | 3/5 (60%) | 0 | 5/5 (100%) | 8/10 (80%) | | 3b | 4/7 (57%) | 0 | 5/5 (100%) | 9/12 (75%) | | 6a | 16/16 (100%) | 26/26 (100%) | 3/3 (100%) | 45/45 (100%) |
|
|
